Mineralys Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
UBS initiated coverage on Mineralys Therapeutics with a neutral rating and a $29 price target. The company's stock is currently trading at $23.37, with a 5-day increase of 4.42% and a year-to-date decrease of 1.10%. Mineralys reported a widened Q2 2026 loss, according to the company.
H.C. Wainwright reiterated a Buy rating and $56.00 price target for Mineralys Therapeutics (NASDAQ:MLYS), citing new clinical data for lorundrostat. The target implies 140% upside from the current stock price of $23.37. The firm highlights the drug's potential in treating difficult-to-treat hypertension ahead of a December 2026 PDUFA date. Mineralys reported a wider-than-expected Q2 2026 loss of $2.85 per share. UBS initiated coverage with a Neutral rating and $29.00 price target.
Mineralys Therapeutics (MLYS) presented data at the American Heart Association Hypertension Scientific Sessions 2026. In the Launch-HTN trial, 46% of participants with difficult-to-treat hypertension achieved the AHA/ACC systolic blood pressure target of <130 mmHg with lorundrostat 50 mg. In the Explore-OSA trial, lorundrostat reduced morning systolic blood pressure by 11.1 mmHg at Week 4. Both trials showed favorable safety and tolerability profiles for lorundrostat.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning MLYS (Mineralys Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent MLYS coverage spans financial news, insider activity and technology.
In the last 30 days, MLYS insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($5.1M). The most active reporter was Warren Eric, Chief Commercial Officer, with 1 filing. 67% of those filings were made under pre-arranged Rule 10b5-1 plans.
UBS initiated coverage on Mineralys Therapeutics with a neutral rating and a $29 price target. The company's stock is currently trading at $23.37, with a 5-day increase of 4.42% and a year-to-date decrease of 1.10%. Mineralys reported a widened Q2 2026 loss, according to the company.
Analyst upgrade with a higher target suggests upside potential.
Positive pivotal trial results likely boost investor confidence and may drive short-term price appreciation.
Insider sale may signal reduced confidence and could pressure the stock lower.
The upcoming presentation could move the stock if data are positive, but no results are disclosed yet.
AlphAI scores every news story that mentions MLYS with an AI model for sentiment and relevance, and aggregates insider trades from Mineralys Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
UBS initiated coverage on Mineralys Therapeutics with a neutral rating and a $29 price target. The company's stock is currently trading at $23.37, with a 5-day increase of 4.42% and a year-to-date decrease of 1.10%. Mineralys reported a widened Q2 2026 loss, according to the company.
1 min readH.C. Wainwright reiterated a Buy rating and $56.00 price target for Mineralys Therapeutics (NASDAQ:MLYS), citing new clinical data for lorundrostat. The target implies 140% upside from the current stock price of $23.37. The firm highlights the drug's potential in treating difficult-to-treat hypertension ahead of a December 2026 PDUFA date. Mineralys reported a wider-than-expected Q2 2026 loss of $2.85 per share. UBS initiated coverage with a Neutral rating and $29.00 price target.
2 min readMineralys Therapeutics (MLYS) presented data at the American Heart Association Hypertension Scientific Sessions 2026. In the Launch-HTN trial, 46% of participants with difficult-to-treat hypertension achieved the AHA/ACC systolic blood pressure target of <130 mmHg with lorundrostat 50 mg. In the Explore-OSA trial, lorundrostat reduced morning systolic blood pressure by 11.1 mmHg at Week 4. Both trials showed favorable safety and tolerability profiles for lorundrostat.
2 min readCongleton Jon (Chief Executive Officer) sold 75,000 shares of Mineralys Therapeutics, Inc. (MLYS) at $25.46 ($1.91M total) on 2026-09-30 under a Rule 10b5-1 trading plan.
1 min readMineralys Therapeutics (MLYS) will present new data from its Launch-HTN trial of lorundrostat at the American Society of Nephrology Kidney Week 2026. The trial, involving patients with uncontrolled hypertension, showed lorundrostat's potential in reducing blood pressure and albuminuria in chronic kidney disease stages 1-3. The company aims to address hypertension and related comorbidities driven by dysregulated aldosterone.
1 min readSlingsby Brian Taylor sold 104,320 indirectly-held shares of Mineralys Therapeutics, Inc. (MLYS) at $28.81 ($3.01M total) on 2026-09-22.
1 min readMineralys Therapeutics (MLYS) officer David Rodman plans to sell 2,171 shares via a cashless option exercise on September 9, 2026, valued at $67,018.77. Rodman has made multiple prior open-market sales, including 14,058 shares on July 13, 2026, for $387,716.51. The transactions are disclosed via Form 144 filings.
1 min readMineralys Therapeutics (MLYS) shares rose after the company acquired future royalty obligations for its lead drug, lorundrostat, potentially increasing long-term profits if approved. Analysts initiated coverage with undervalued ratings, and institutional buying was reported ahead of the FDA's 2026 decision. The stock has fallen 30.37% YTD, with a market cap of $2.27B. Risks include clinical setbacks and financial strain due to cash burn and debt.
2 min readMineralys Therapeutics (MLYS) reported a Q2 2026 net loss of $241.07M. The company appointed James J. Ferguson III, M.D., as Chief Medical Officer. Shares are down 5.04% in 30 days and 14.07% in 90 days, but up 72.32% in 1 year and 97.31% in 3 years. Analysts suggest fair value at $50.88, above the current $25.65, based on lorundrostat's potential. Risks include regulatory outcomes and cash burn.
2 min readMineralys Therapeutics (MLYS) officer Eric Warren filed a Rule 144 notice to sell 7,437 shares on 08/21/2026 via employee stock options. Warren previously sold 104,124 shares for $2.7M on 06/26/2026 and 7,438 shares for $199,884.80 on 07/21/2026. The planned sale is valued at $193,188.40.
1 min read